Search Result

Results for "

CD3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	c-Kit (3) CD19 (4) CD2 (1) CD20 (7) CD22 (1) CD28 (5) CD3 (95) CD38 (4) CD44 (1) CTLA-4 (1) FLT3 (2) 5-HT Receptor (11) Acetolactate Synthase (ALS) (1) ADC Antibody (1) ADC Payload (2) Adenosine Receptor (1) Adrenergic Receptor (8) Akt (1) Amino Acid Derivatives (1) Androgen Receptor (3) Angiotensin Receptor (1) Antibiotic (18) Apoptosis (25) Aryl Hydrocarbon Receptor (2) Atg8/LC3 (1) Autophagy (26) Bacterial (20) Bcr-Abl (3) BCRP (1) Biochemical Assay Reagents (1) c-Fms (1) Cadherin (1) Calcium Channel (5) Caspase (1) Claudin (3) COX (10) CXCR (1) Cytochrome P450 (6) Dipeptidyl Peptidase (3) DNA/RNA Synthesis (4) Dopamine Receptor (8) Drug Derivative (1) Drug Intermediate (1) Drug Metabolite (8) EGFR (6) Elastase (1) Endogenous Metabolite (20) Estrogen Receptor/ERR (2) FAAH (1) Factor Xa (1) Ferroptosis (3) FGFR (3) FKBP (1) Folate Receptor (FR) (1) Fungal (4) Glucocorticoid Receptor (1) GnRH Receptor (1) HCV (4) HCV Protease (1) Herbicide (1) Histamine Receptor (11) HIV (6) HIV Integrase (1) HIV Protease (1) HMG-CoA Reductase (HMGCR) (2) HSV (1) IFNAR (8) Imidazoline Receptor (2) Influenza Virus (3) Interleukin Related (15) Isotope-Labeled Compounds (196) Itk (1) JAK (2) LDLR (1) Leukotriene Receptor (1) Liposome (1) mAChR (1) MAP4K (2) MDM-2/p53 (1) MEK (1) MHC (1) Microtubule/Tubulin (3) Mineralocorticoid Receptor (1) Mitochondrial Metabolism (1) Mitophagy (1) MMP (1) mTOR (2) Mucin (1) Na+/K+ ATPase (1) Neurokinin Receptor (1) NF-κB (1) NO Synthase (1) Notch (3) Nuclear Factor of activated T Cells (NFAT) (1) Nucleoside Antimetabolite/Analog (1) Opioid Receptor (1) Orexin Receptor (OX Receptor) (1) P2Y Receptor (1) p38 MAPK (1) Parasite (10) PARP (1) PD-1/PD-L1 (10) PDGFR (6) Phosphatase (1) Phosphodiesterase (PDE) (2) PI3K (1) PKC (1) Potassium Channel (3) Progesterone Receptor (2) PROTACs (2) Proton Pump (3) PSMA (2) Quinone Reductase (1) Raf (3) Reactive Oxygen Species (ROS) (2) Reference Standards (1) RET (1) Reverse Transcriptase (1) ROR (1) SARS-CoV (8) Serotonin Transporter (1) Small Interfering RNA (siRNA) (11) Sodium Channel (2) Src (3) TGF-beta/Smad (1) Thrombin (1) Thyroid Hormone Receptor (2) TNF Receptor (15) Topoisomerase (2) Transmembrane Glycoprotein (7) VD/VDR (1) VEGFR (7) VKOR (1)
By Research Areas:	Cancer (153) Cardiovascular Disease (18) Endocrinology (19) Infection (39) Inflammation/Immunology (90) Metabolic Disease (23) Neurological Disease (35)
Click Chemistry:	Azide (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (3) Cationic Lipids (1) Mouse Pre-designed siRNA Sets (4) Human Pre-designed siRNA Sets (4) siRNAs (11)

365

Inhibitors & Agonists

Peptides

MCE Kits

114

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

215

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Teclistamab JNJ-7957; JNJ-64007957; Tecvayli	CD3	Cancer
Teclistamab is a human bispecific antibody to BCMA and *CD3* that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .

Mosunetuzumab 1 Publications Verification BTCT-4465A; RG-7828; RO7030816	CD20 CD3	Inflammation/Immunology Cancer
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and *CD3* (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .

Glofitamab 1 Publications Verification RO7082859; RG-6026	CD20 CD3	Inflammation/Immunology Cancer
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for *CD3* on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) ^[3] .

Cevostamab BFCR 4350A; RG 6160; RO 7187797	CD3	Neurological Disease Cancer
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as *CD3* on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .

Solitomab AMG 110	CD3	Cancer
Solitomab (AMG 110) is a bispecific *anti-CD3* and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer .

Epcoritamab 1 Publications Verification GEN3013	CD3 CD20	Cancer
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 ⁺ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .

*Anti-CD3* Antibody (OKT-3)**	CD3	Inflammation/Immunology
Anti-CD3 Antibody (OKT-3) is a kind of mouse IgG2a κ antibody inhibitor, targeting to human *CD3. Anti-CD3* Antibody (OKT-3) decreases T cells. Anti-CD3 Antibody (OKT-3) can be used for the research of immunology, such as graft-versus-host disease ^[3].

Surovatamig AZD0486; TNB-486	CD3 CD19 Interleukin Related TNF Receptor IFNAR	Cancer
Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma .

Xaluritamig AMG-509	CD3	Cancer
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a K_d of 27.6 nM for human *CD3ε. Xaluritamig binds to CD3ε* via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8 ⁺ T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in *STEAP1×CD3* XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma ^[3].

Pasritamig JNJ-78278343; KLCB-245	CD3	Cancer
Pasritamig (JNJ-78278343; KLCB-245) is a bispecific T-cell engager (BiTE) that targets the complex of human kallikrein KLK2 and *CD3* receptor. Pasritamig redirects the cytotoxicity of T cells to KLK2-expressing tumor cells and induces T cell-mediated lysis of KLK2-expressing prostate cancer cells. Administered via subcutaneous injection, subcutaneous infusion or intravenous infusion, Pasritamig exhibits antitumor activity against metastatic castration-resistant prostate cancer. Pasritamig has a safety profile with an extremely low incidence of cytokine release syndrome and can be safely administered in an outpatient setting. Pasritamig is applicable to the research of metastatic castration-resistant prostate cancer ^[3] .

Ubamatamab REGN4018	CD3	Cancer
Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and *CD3*. Ubamatamab demonstrates potent antitumor activity .

Talquetamab 1 Publications Verification JNJ-64407564	CD3	Cancer
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and *CD3* to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .

Pasotuxizumab 1 Publications Verification BAY 2010112; AMG 212; MT112	CD3	Cancer
Pasotuxizumab (BAY 2010112) is a PSMA and *CD3* bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with K_Ds of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

Voxalatamab JNJ-63898081; JNJ-081	CD3 PSMA	Cancer
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and *CD3. Voxalatamab attacks PSMA*-expressing tumor cells by activating T cells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer .

Obrindatamab 1 Publications Verification MGD009	CD3	Cancer
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .

Vibecotamab XmAb14045	CD3	Inflammation/Immunology Cancer
Vibecotamab (XmAb14045) is a potent bispecific antibody targeting both CD123 and *CD3*. Vibecotamab targets T cell-mediated killing of CD123-expressing cells, regardless of T cell antigen specificity. Vibecotamab is a full length immunoglobulin molecule. Vibecotamab can be studied in research for diseases such as Myelodysplastic syndrome and acute myeloid leukemia. Recommend Isotype Control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3 ^[3].

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human *CD3* monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .

Cibisatamab 2 Publications Verification	CD3	Cancer
Cibisatamab, a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and *CD3* on T cells. Cibisatamab triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab can be used for colorectal cancer research .

Runimotamab BTRC-4017A; RG-6194	EGFR CD3	Cancer
Runimotamab (BTRC-4017A) is a HER2 and *CD3* T cell-engaging bispecific antibody. Runimotamab can decrease the size of liver tumor spheroids. Runimotamab can be studied in oncology research such as HER2-expressing cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

Obrixtamig BI 764532; OBT 620	CD3	Cancer
Obrixtamig (BI 764532; OBT 620) is an *CD3E/DLL3*-targeting L-κ-G1-h-CH2-CH3_L-λ-G1-h-CH2-CH3 type human antibody. Obrixtamig is a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager. Obrixtamig can be used for research of DLL3-positive small cell lung cancer .

Tebentafusp IMCgp100	Interleukin Related TNF Receptor	Cancer
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3* T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .

Odronextamab REGN1979	CD20 CD3	Inflammation/Immunology Cancer
Odronextamab is a stable humanized IgG4 CD20 × *CD3* bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .

Gresonitamab 1 Publications Verification AMG 910; Anti-Human CD3xClaudin18 2	CD3	Cancer
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets *CD3*-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .

Brenetafusp IMC-F106C	CD3	Cancer
Brenetafusp is a TCR/anti-CD3 bispecific fusion protein, consisting of a TCR targeting the PRAME peptide and an anti-CD3 scFv effector domain. Brenetafusp redirects *CD3* ⁺ T cells to kill PRAME ⁺ tumor cells. Brenetafusp can be used in research related to cutaneous melanoma, non-small cell lung cancer, ovarian cancer, endometrial cancer, triple-negative breast cancer, and small cell lung cancer .

Etevritamab AMG-596	EGFR CD3	Neurological Disease Cancer
Etevritamab (AMG-596) is a bispecific T-cell engager that targets EGFRvIII and *CD3. Etevritamab simultaneously binds CD3* on T cells and EGFRvIII on glioblastoma multiforme cells, thereby forming a bridge structure. Etevritamab triggers T-cell activation, proliferation, secretion of cytotoxic substances, and tumor cell lysis. Etevritamab extends overall survival and induces tumor regression in mouse models of glioblastoma multiforme. Etevritamab can be used for research related to glioblastoma .

Muromonab Muromanab-CD3	CD3 Interleukin Related IFNAR	Inflammation/Immunology Cancer
Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonal antibody targeting the *CD3* antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate T cells. Muromonab blocks the function of T cell receptors to recognize foreign antigens and inhibits T cell-mediated immune responses, including cell-mediated lymphocyte lysis and T cell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients ^[3] .

Visilizumab Anti-Human CD3E Recombinant Antibody; HuM291	Apoptosis	Inflammation/Immunology Cancer
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .

Linclatamig BLYG8824A; RG6286	CD3	Inflammation/Immunology
Linclatamig (BLYG8824A) is a humanized IgG1 T-cell engaging bispecific antibody (TCB) targeting LY6G6D and *CD3. Linclatamig can bind to LY6G6D and CD3-positive* T cells, forming an immunological synapse to promote T cell-mediated killing of LY6G6D-positive cells. Linclatamig can be used in colorectal cancer research .

Alveltamig ZG006	CD3 Notch	Neurological Disease Cancer
Alveltamig (ZG006) is a trispecific T cell engager targeting Delta-like ligand 3 (DLL3)/CD3, mediating T cell-specific killing of DLL3-expressing tumor cells. Alveltamig can be used for the researches of small cell lung cancer and neuroendocrine carcinoma .

Cizutamig CND-106; EMB-06	CD3	Inflammation/Immunology Cancer
Cizutamig (CND-106) is a bispecific T-cell engager targeting BCMA and *CD3*. Cizutamig exhibits immunostimulatory and anti-tumor activities. Cizutamig can be used in research related to relapsed or refractory multiple myeloma and systemic lupus erythematosus .

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational *CD123/CD3* bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and *CD3* in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .

ISB2001	CD38 CD3 TNF Receptor	Cancer
ISB2001 is a trispecific antibody targeting CD38, *CD3* and BCMA. ISB2001 effectively counteracts tumor immune escape mechanisms caused by antigen downregulation, antigen loss, soluble factor competition and other factors. ISB2001 is applicable to relevant research on multiple myeloma and relapsed/refractory multiple myeloma .

*Anti-Mouse CD3* Antibody (17A2)** 1 Publications Verification	CD3	Inflammation/Immunology
Anti-Mouse CD3 Antibody (17A2) is an anti-mouse CD3 IgG2b antibody inhibitor derived from the host Rat. Anti-Mouse CD3 Antibody (17A2) enhances T-cell proliferation and activation and stimulate IFN-γ or IL-17 production in splenic T cells. Anti-Mouse CD3 Antibody (17A2) significantly suppresses mortality in Graft-versus-host disease (GVHD) mice models .

Alnuctamab EM901; CC-93269	CD3	Inflammation/Immunology Cancer
Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and *CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA* expressed on the surface of myeloma cells and *CD3* molecules on the surface of T cells, recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) ^[3].

Foralumab NI-0401	CD3	Inflammation/Immunology
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the *CD3*. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .

Linvoseltamab REGN5458	CD3 TNF Receptor	Cancer
Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody that specifically binds to B cell maturation antigen (BCMA) and CD3 of T cells, thereby directing T cells to multiple myeloma (MM) cells expressing BCMA and activating T cells to kill tumor cells. Linvoseltamab can be used in research of relapsed/refractory multiple myeloma (RRMM) ^[3].

Clesitamig ALPS-12; RG-6524; RO 7616789	CD3	Inflammation/Immunology Cancer
Clesitamig (ALPS-12) is a trispecific T cell engager with two *CD3/CD137* dual-specific Fabs and one DLL3 Fab. Clesitamig engages CD3 and CD137 on T cells to activate and co-stimulate T cells, promoting their proliferation, survival, and antitumor activity. Clesitamig binds to DLL3 on tumor cells for tumor-specific recognition. Clesitamig can be used for the research of small cell lung cancer (SCLC) .

Eluvixtamab AMG-330	CD3 Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Eluvixtamab (AMG-330) is a bispecific T-cell engager. Eluvixtamab binds to CD33 and *CD3* on T cells, thereby promoting T cell-mediated cytotoxicity against CD33+ cells. Eluvixtamab can be used in the research of tumors such as relapsed/refractory acute myeloid leukemia .

M701	CD3	Cancer
M701 is a T-cell engager bispecific humanized antibody targeting epithelial cell adhesion molecule (EpCAM) and cluster of differentiation 3 (CD3). M701 binds to EpCAM on tumor cells and *CD3* on T cells, thereby linking the two cell populations to achieve targeted cytotoxicity and T cell-mediated cytotoxicity. M701 is applicable to research related to advanced epithelial solid tumors .

Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757)	Notch	Inflammation/Immunology Cancer
Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757) is the anti-DLL3 arm of the bispecific T-cell engager (BiTE) antibody-Tarlatamab (AMG-757) (HY-P99575). Tarlatamab targets both DLL3 and CD3.

Tidutamab XmAb-18087	CD3	Cancer
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .

PROTAC PD-1/PD-L1 degrader-1	PROTACs PD-1/PD-L1	Inflammation/Immunology
PROTAC PD-1/PD-L1 degrader-1, a PD-1/PD-L1 PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC₅₀ of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner .

Vepsitamab AMG 199	CD3	Cancer
Vepsitamab (AMG 199) is a bispecific T-cell engager (HLE BiTE) that binds to MUC17 and *CD3. Vepsitamab directs CD3-positive* cells to target MUC17-positive cells. Vepsitamab induces cell activation and proliferation. Vepsitamab is applicable to research related to gastric cancer and gastroesophageal junction (g/gej) cancer .

Vonsetamig REGN5459	CD3 TNF Receptor	Cancer
Vonsetamig (REGN5459) is a human bispecific antibody targeting BCMA and *CD3*. Vonsetamig triggers T-cell activation, induces plasma cell depletion, and triggers low-level cytokine release. Vonsetamig can be used for the research of relapsed/refractory multiple myeloma .

Nivatrotamab Hu3F8-BsAb	CD2 CD3	Cancer
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma .

Etentamig ABBV-383; TNB 383B	CD3	Cardiovascular Disease Inflammation/Immunology Cancer
Etentamig is a BCMA × *CD3* bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein *CD3* complex. Etentamig can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases .

Cat. No.	Product Name	Target	Research Area

HY-P11483

FJ15596	PD-1/PD-L1	Inflammation/Immunology Cancer
FJ15596 is a PD-1/PD-L1 blockor. FJ15596 blocks PD-1/PD-L1 binding with an IC₅₀ of 570 nM. FJ15596 restores CD3 ⁺ T cell viability. FJ15596 can be used in cancer immunology research .

HY-P11490

DPMI-ω	MDM-2/p53	Inflammation/Immunology Cancer
DPMI-ω is a dual-specificity d-peptide antagonist of oncogenic proteins MDM2 and MDMX. DPMI-ω, upon fabrication on gold nanoparticles, efficiently traverses tumor cells and kills them by reactivating the p53 signaling pathway. DPMI-ω can disrupte the p53-MDM2/MDMX complex. DPMI-ω can inhibit B16 melanoma growth and induce cells G0/G1 phase arrest. DPMI-ω can augment the efficacy of immunotherapy by expanding CD3 ⁺/CD8 ⁺ cytotoxic T cells and suppressing CD4 ⁺/CD25 ⁺ regulatory T cells companied with anti-PD1 antibody. DPMI-ω can be used for research of melanoma .

Cat. No.	Product Name

HY-K0304

*Human CD3⁺ T Cells Negative Selection Kit*
MCE Human CD3⁺ T Cells Negative Selection Kit is designed for the isolation of CD3⁺ T cells from human peripheral blood mononuclear cells (PBMC).

HY-K0306

*Mouse CD3⁺ T Cells Negative Selection Kit*
MCE Mouse CD3⁺ T Cells Negative Selection Kit is designed for the isolation of CD3⁺ T cells from single cell suspensions of mouse spleen cells and lymph nodes.

HY-K0353

*Human CD3/CD28 T Cell Activation Magnetic Beads* 1 Publications Verification
MCE Human CD3/CD28 T Cell Activation Magnetic Beads are based on the two important co-stimulatory signals, without relying on feeder cells (antigen-presenting cells) or antigens, CD3 and CD28, without relying on feeder cells (antigen-presenting cells) or antigens, enabling simple and rapid T cell activation.

HY-K0354

*Mouse CD3/CD28 T Cell Activation Magnetic Beads*
MCE Mouse CD3/CD28 T Cell Activation Magnetic Beads are based on the two important co-stimulatory signals, without relying on feeder cells (antigen-presenting cells) or antigens, CD3 and CD28, without relying on feeder cells (antigen-presenting cells) or antigens, enabling simple and rapid T cell activation.

Cat. No.	Product Name	Target	Research Area	Image

HY-P99575

Tarlatamab 1 Publications Verification AMG-757	Notch	Inflammation/Immunology Cancer
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the K_Ds of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the K_Ds of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .

HY-P99392

Teclistamab JNJ-7957; JNJ-64007957; Tecvayli	CD3	Cancer
Teclistamab is a human bispecific antibody to BCMA and *CD3* that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .

HY-P99033

Mosunetuzumab 1 Publications Verification BTCT-4465A; RG-7828; RO7030816	CD20 CD3	Inflammation/Immunology Cancer
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and *CD3* (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .

HY-P99024

Glofitamab 1 Publications Verification RO7082859; RG-6026	CD20 CD3	Inflammation/Immunology Cancer
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for *CD3* on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) ^[3] .

HY-P99601

Cevostamab BFCR 4350A; RG 6160; RO 7187797	CD3	Neurological Disease Cancer
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as *CD3* on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .

HY-P99592

Solitomab AMG 110	CD3	Cancer
Solitomab (AMG 110) is a bispecific *anti-CD3* and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer .

HY-P99931

Epcoritamab 1 Publications Verification GEN3013	CD3 CD20	Cancer
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 ⁺ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .

HY-P990864

*Anti-CD3* Antibody (OKT-3)**	CD3	Inflammation/Immunology
Anti-CD3 Antibody (OKT-3) is a kind of mouse IgG2a κ antibody inhibitor, targeting to human *CD3. Anti-CD3* Antibody (OKT-3) decreases T cells. Anti-CD3 Antibody (OKT-3) can be used for the research of immunology, such as graft-versus-host disease ^[3].

HY-P991028

Surovatamig AZD0486; TNB-486	CD3 CD19 Interleukin Related TNF Receptor IFNAR	Cancer
Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma .

HY-P990688

Xaluritamig AMG-509	CD3	Cancer
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a K_d of 27.6 nM for human *CD3ε. Xaluritamig binds to CD3ε* via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8 ⁺ T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in *STEAP1×CD3* XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma ^[3].

HY-P991015

Pasritamig JNJ-78278343; KLCB-245	CD3	Cancer
Pasritamig (JNJ-78278343; KLCB-245) is a bispecific T-cell engager (BiTE) that targets the complex of human kallikrein KLK2 and *CD3* receptor. Pasritamig redirects the cytotoxicity of T cells to KLK2-expressing tumor cells and induces T cell-mediated lysis of KLK2-expressing prostate cancer cells. Administered via subcutaneous injection, subcutaneous infusion or intravenous infusion, Pasritamig exhibits antitumor activity against metastatic castration-resistant prostate cancer. Pasritamig has a safety profile with an extremely low incidence of cytokine release syndrome and can be safely administered in an outpatient setting. Pasritamig is applicable to the research of metastatic castration-resistant prostate cancer ^[3] .

HY-P99539

Ubamatamab REGN4018	CD3	Cancer
Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and *CD3*. Ubamatamab demonstrates potent antitumor activity .

HY-P99394

Talquetamab 1 Publications Verification JNJ-64407564	CD3	Cancer
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and *CD3* to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .

HY-P99434

Amlitelimab KY1005; SAR445229	Inhibitory Antibodies	Inflammation/Immunology
Amlitelimab () is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb). Amlitelimab inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis ^[3].

HY-P99802

Pasotuxizumab 1 Publications Verification BAY 2010112; AMG 212; MT112	CD3	Cancer
Pasotuxizumab (BAY 2010112) is a PSMA and *CD3* bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with K_Ds of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

HY-P99517

Voxalatamab JNJ-63898081; JNJ-081	CD3 PSMA	Cancer
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and *CD3. Voxalatamab attacks PSMA*-expressing tumor cells by activating T cells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer .

HY-P99762

Obrindatamab 1 Publications Verification MGD009	CD3	Cancer
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .

HY-P99521

Vibecotamab XmAb14045	CD3	Inflammation/Immunology Cancer
Vibecotamab (XmAb14045) is a potent bispecific antibody targeting both CD123 and *CD3*. Vibecotamab targets T cell-mediated killing of CD123-expressing cells, regardless of T cell antigen specificity. Vibecotamab is a full length immunoglobulin molecule. Vibecotamab can be studied in research for diseases such as Myelodysplastic syndrome and acute myeloid leukemia. Recommend Isotype Control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3 ^[3].

HY-P99222

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human *CD3* monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .

HY-P99011

Cibisatamab 2 Publications Verification	CD3	Cancer
Cibisatamab, a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and *CD3* on T cells. Cibisatamab triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab can be used for colorectal cancer research .

HY-P99896

Runimotamab BTRC-4017A; RG-6194	EGFR CD3	Cancer
Runimotamab (BTRC-4017A) is a HER2 and *CD3* T cell-engaging bispecific antibody. Runimotamab can decrease the size of liver tumor spheroids. Runimotamab can be studied in oncology research such as HER2-expressing cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990932

Obrixtamig BI 764532; OBT 620	CD3	Cancer
Obrixtamig (BI 764532; OBT 620) is an *CD3E/DLL3*-targeting L-κ-G1-h-CH2-CH3_L-λ-G1-h-CH2-CH3 type human antibody. Obrixtamig is a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager. Obrixtamig can be used for research of DLL3-positive small cell lung cancer .

HY-P99339

Tebentafusp IMCgp100	Interleukin Related TNF Receptor	Cancer
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3* T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .

HY-P99038

Odronextamab REGN1979	CD20 CD3	Inflammation/Immunology Cancer
Odronextamab is a stable humanized IgG4 CD20 × *CD3* bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .

HY-P99350

Gresonitamab 1 Publications Verification AMG 910; Anti-Human CD3xClaudin18 2	CD3	Cancer
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets *CD3*-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .

HY-P990717

Brenetafusp IMC-F106C	CD3	Cancer
Brenetafusp is a TCR/anti-CD3 bispecific fusion protein, consisting of a TCR targeting the PRAME peptide and an anti-CD3 scFv effector domain. Brenetafusp redirects *CD3* ⁺ T cells to kill PRAME ⁺ tumor cells. Brenetafusp can be used in research related to cutaneous melanoma, non-small cell lung cancer, ovarian cancer, endometrial cancer, triple-negative breast cancer, and small cell lung cancer .

HY-P9954

Catumaxomab	CD3	Cancer
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human *CD 3* receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .

HY-P99948

Etevritamab AMG-596	EGFR CD3	Neurological Disease Cancer
Etevritamab (AMG-596) is a bispecific T-cell engager that targets EGFRvIII and *CD3. Etevritamab simultaneously binds CD3* on T cells and EGFRvIII on glioblastoma multiforme cells, thereby forming a bridge structure. Etevritamab triggers T-cell activation, proliferation, secretion of cytotoxic substances, and tumor cell lysis. Etevritamab extends overall survival and induces tumor regression in mouse models of glioblastoma multiforme. Etevritamab can be used for research related to glioblastoma .

HY-P99152

Muromonab Muromanab-CD3	CD3 Interleukin Related IFNAR	Inflammation/Immunology Cancer
Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonal antibody targeting the *CD3* antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate T cells. Muromonab blocks the function of T cell receptors to recognize foreign antigens and inhibits T cell-mediated immune responses, including cell-mediated lymphocyte lysis and T cell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients ^[3] .

HY-P99332

Visilizumab Anti-Human CD3E Recombinant Antibody; HuM291	Apoptosis	Inflammation/Immunology Cancer
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .

HY-P990925

Linclatamig BLYG8824A; RG6286	CD3	Inflammation/Immunology
Linclatamig (BLYG8824A) is a humanized IgG1 T-cell engaging bispecific antibody (TCB) targeting LY6G6D and *CD3. Linclatamig can bind to LY6G6D and CD3-positive* T cells, forming an immunological synapse to promote T cell-mediated killing of LY6G6D-positive cells. Linclatamig can be used in colorectal cancer research .

HY-P991731

Alveltamig ZG006	CD3 Notch	Neurological Disease Cancer
Alveltamig (ZG006) is a trispecific T cell engager targeting Delta-like ligand 3 (DLL3)/CD3, mediating T cell-specific killing of DLL3-expressing tumor cells. Alveltamig can be used for the researches of small cell lung cancer and neuroendocrine carcinoma .

HY-P990980

Cizutamig CND-106; EMB-06	CD3	Inflammation/Immunology Cancer
Cizutamig (CND-106) is a bispecific T-cell engager targeting BCMA and *CD3*. Cizutamig exhibits immunostimulatory and anti-tumor activities. Cizutamig can be used in research related to relapsed or refractory multiple myeloma and systemic lupus erythematosus .

HY-P99623

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational *CD123/CD3* bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and *CD3* in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .

HY-P991490

ISB2001	CD38 CD3 TNF Receptor	Cancer
ISB2001 is a trispecific antibody targeting CD38, *CD3* and BCMA. ISB2001 effectively counteracts tumor immune escape mechanisms caused by antigen downregulation, antigen loss, soluble factor competition and other factors. ISB2001 is applicable to relevant research on multiple myeloma and relapsed/refractory multiple myeloma .

HY-P99124

*Anti-Mouse CD3* Antibody (17A2)** 1 Publications Verification	CD3	Inflammation/Immunology
Anti-Mouse CD3 Antibody (17A2) is an anti-mouse CD3 IgG2b antibody inhibitor derived from the host Rat. Anti-Mouse CD3 Antibody (17A2) enhances T-cell proliferation and activation and stimulate IFN-γ or IL-17 production in splenic T cells. Anti-Mouse CD3 Antibody (17A2) significantly suppresses mortality in Graft-versus-host disease (GVHD) mice models .

HY-P99430

Alnuctamab EM901; CC-93269	CD3	Inflammation/Immunology Cancer
Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and *CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA* expressed on the surface of myeloma cells and *CD3* molecules on the surface of T cells, recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) ^[3].

HY-P99868

Duvortuxizumab MGD 011	CD19 CD3	Cancer
Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E .

HY-P99199

Foralumab NI-0401	CD3	Inflammation/Immunology
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the *CD3*. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .

HY-P9989

Linvoseltamab REGN5458	CD3 TNF Receptor	Cancer
Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody that specifically binds to B cell maturation antigen (BCMA) and CD3 of T cells, thereby directing T cells to multiple myeloma (MM) cells expressing BCMA and activating T cells to kill tumor cells. Linvoseltamab can be used in research of relapsed/refractory multiple myeloma (RRMM) ^[3].

HY-P990802

*Anti-Mouse CD3ε Antibody (145-2C11)*	CD3	Metabolic Disease Inflammation/Immunology
Anti-Mouse CD3ε Antibody (145-2C11) is an orally active anti-mouse *CD3ε* IgG1 monoclonal antibody. Anti-Mouse CD3ε Antibody (145-2C11) can inhibit the proliferation of effector T cells and improve the function of regulatory T cells (Tregs). Anti-Mouse CD3ε Antibody (145-2C11) relieves inflammatory response by inhibiting the production of pro-inflammatory cytokines and increasing the secretion of anti-inflammatory factors. Anti-Mouse CD3ε Antibody (145-2C11) can be used for researches on metabolic and immune system conditions such as diabetes and lupus. The recommend isotype control of Anti-Mouse CD3ε Antibody (145-2C11): Armenian hamster IgG, Isotype Control (HY-P990305) .

HY-P990981

Clesitamig ALPS-12; RG-6524; RO 7616789	CD3	Inflammation/Immunology Cancer
Clesitamig (ALPS-12) is a trispecific T cell engager with two *CD3/CD137* dual-specific Fabs and one DLL3 Fab. Clesitamig engages CD3 and CD137 on T cells to activate and co-stimulate T cells, promoting their proliferation, survival, and antitumor activity. Clesitamig binds to DLL3 on tumor cells for tumor-specific recognition. Clesitamig can be used for the research of small cell lung cancer (SCLC) .

HY-P99910

Eluvixtamab AMG-330	CD3 Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Eluvixtamab (AMG-330) is a bispecific T-cell engager. Eluvixtamab binds to CD33 and *CD3* on T cells, thereby promoting T cell-mediated cytotoxicity against CD33+ cells. Eluvixtamab can be used in the research of tumors such as relapsed/refractory acute myeloid leukemia .

HY-P991526

M701	CD3	Cancer
M701 is a T-cell engager bispecific humanized antibody targeting epithelial cell adhesion molecule (EpCAM) and cluster of differentiation 3 (CD3). M701 binds to EpCAM on tumor cells and *CD3* on T cells, thereby linking the two cell populations to achieve targeted cytotoxicity and T cell-mediated cytotoxicity. M701 is applicable to research related to advanced epithelial solid tumors .

HY-P990104

Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757)	Notch	Inflammation/Immunology Cancer
Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757) is the anti-DLL3 arm of the bispecific T-cell engager (BiTE) antibody-Tarlatamab (AMG-757) (HY-P99575). Tarlatamab targets both DLL3 and CD3.

HY-P99562

Tidutamab XmAb-18087	CD3	Cancer
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .

HY-P99523

Vepsitamab AMG 199	CD3	Cancer
Vepsitamab (AMG 199) is a bispecific T-cell engager (HLE BiTE) that binds to MUC17 and *CD3. Vepsitamab directs CD3-positive* cells to target MUC17-positive cells. Vepsitamab induces cell activation and proliferation. Vepsitamab is applicable to research related to gastric cancer and gastroesophageal junction (g/gej) cancer .

HY-P990095

Vonsetamig REGN5459	CD3 TNF Receptor	Cancer
Vonsetamig (REGN5459) is a human bispecific antibody targeting BCMA and *CD3*. Vonsetamig triggers T-cell activation, induces plasma cell depletion, and triggers low-level cytokine release. Vonsetamig can be used for the research of relapsed/refractory multiple myeloma .

HY-P99757

Nivatrotamab Hu3F8-BsAb	CD2 CD3	Cancer
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma .

HY-P990785

Etentamig ABBV-383; TNB 383B	CD3	Cardiovascular Disease Inflammation/Immunology Cancer
Etentamig is a BCMA × *CD3* bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein *CD3* complex. Etentamig can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases .

Species:	Human (25) Rhesus Macaque (4) Rat (1) Mouse (9) Cynomolgus (17) Canine (4)
Tag:	His (29) Tag Free (1) Avi (10) Fc (36) Flag (9)
Source:	HEK293 (58) P. pastoris (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P704103

	CD3D-CD3E Heterodimer Protein, Cynomolgus (HEK293, His, flag) CD3; CD3e; CD3E; CD3d; T3D; CD3D; CD3E&CD3D; CD3 delta&CD3 epsilon	Cynomolgus	HEK293

HY-P700677

	CD3D-CD3E Heterodimer Protein, Human (Biotinylated, HEK293, His) CD3; CD3e; CD3E; CD3d; T3D; CD3D; CD3E&CD3D; CD3 delta&CD3 epsilon	Human	HEK293
	CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3E-CD3D Heterodimer Protein, Human (Biotinylated, HEK293, His) is a recombinant protein dimer complex containing human-derived CD3E-CD3D Heterodimer protein, expressed by HEK293 , with C-His labeled tag. CD3E-CD3D Heterodimer Protein, Human (Biotinylated, HEK293, His), has molecular weight of 25-40 kDa.

HY-P77603

	CD3D-CD3E Heterodimer Protein, Cynomolgus (HEK293, Fc) CD3; CD3e; CD3E; CD3d; T3D; CD3D; CD3E&CD3D; CD3 delta&CD3 epsilon	Cynomolgus	HEK293
	The CD3E/CD3 epsilon 1-27 peptide is critical in the TCR-CD3 complex, transmitting signals during T cell activation. When APC activates the TCR, CD3E undergoes LCK/FYN-mediated phosphorylation together with ITAM, initiating downstream signaling. CD3D-CD3E Heterodimer Protein, Cynomolgus (HEK293, Fc) is a recombinant protein dimer complex containing cynomolgus-derived CD3D-CD3E Heterodimer protein, expressed by HEK293 , with C-hFc labeled tag. CD3D-CD3E Heterodimer Protein, Cynomolgus (HEK293, Fc), has molecular weight of 58-62 kDa.

HY-P700678

	CD3E-CD3G Heterodimer Protein, Human (Biotinylated, HEK293, His) CD3; CD3G; CD3g; T3G; CD3e; CD3E; CD3 epsilon&CD3 gamma; CD3E&CD3G	Human	HEK293
	CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3E-CD3G Heterodimer Protein, Human (Biotinylated, HEK293, His) is a recombinant protein dimer complex containing human-derived CD3E-CD3G Heterodimer protein, expressed by HEK293 , with C-His labeled tag. CD3E-CD3G Heterodimer Protein, Human (Biotinylated, HEK293, His), has molecular weight of 25-40 kDa.

HY-P77610

	CD3D-CD3E Heterodimer Protein, Human (HEK293, Fc) CD3; CD3e; CD3E; CD3d; T3D; CD3D; CD3E&CD3D; CD3 delta&CD3 epsilon	Human	HEK293
	CD3D protein is a component of the TCR-CD3 complex on T lymphocytes and plays a key role in adaptive immunity. It transmits signals through the CD3D, CD3E, CD3G, and CD3Z chains upon TCR engagement. CD3D-CD3E Heterodimer Protein, Human (HEK293, Fc) is a recombinant protein dimer complex containing human-derived CD3D-CD3E Heterodimer protein, expressed by HEK293 , with C-hFc labeled tag. CD3D-CD3E Heterodimer Protein, Human (HEK293, Fc), has molecular weight of 40-53 kDa.

HY-P77614

	CD3D-CD3E Heterodimer Protein, Mouse (HEK293, Fc) CD3; CD3e; CD3E; CD3d; T3D; CD3D; CD3E&CD3D; CD3 delta&CD3 epsilon	Mouse	HEK293
	The CD3D protein is an important component of the TCR-CD3 complex on T lymphocytes and is critical for adaptive immune responses. After APC activates TCR, CD3D, together with CD3E, CD3G and CD3Z, transmits signals through ITAM and activates downstream pathways. CD3D-CD3E Heterodimer Protein, Mouse (HEK293, Fc) is a recombinant protein dimer complex containing mouse-derived CD3D-CD3E Heterodimer protein, expressed by HEK293 , with C-hFc labeled tag. CD3D-CD3E Heterodimer Protein, Mouse (HEK293, Fc), has molecular weight of 50-65 kDa.

HY-P77604

	CD3D-CD3E Heterodimer Protein, Cynomolgus (Biotinylated, HEK293, Fc) CD3; CD3e; CD3E; CD3d; T3D; CD3D; CD3E&CD3D; CD3 delta&CD3 epsilon	Cynomolgus	HEK293
	The CD3E/CD3 epsilon 1-27 peptide is critical in the TCR-CD3 complex, transmitting signals during T cell activation. When APC activates the TCR, CD3E undergoes LCK/FYN-mediated phosphorylation together with ITAM, initiating downstream signaling. CD3D-CD3E Heterodimer Protein, Cynomolgus (Biotinylated, HEK293, Fc) is a recombinant protein dimer complex containing cynomolgus-derived CD3D-CD3E Heterodimer protein, expressed by HEK293 , with C-hFc labeled tag. CD3D-CD3E Heterodimer Protein, Cynomolgus (Biotinylated, HEK293, Fc), has molecular weight of 58-62 kDa.

HY-P77606

	CD3E-CD3G Heterodimer Protein, Cynomolgus (Biotinylated, HEK293, Fc) CD3; CD3G; CD3g; T3G; CD3e; CD3E; CD3 epsilon&CD3 gamma; CD3E&CD3G	Cynomolgus	HEK293
	The CD3E/CD3 epsilon 1-27 peptide is critical in the TCR-CD3 complex, transmitting signals during T cell activation. When APC activates the TCR, CD3E undergoes LCK/FYN-mediated phosphorylation together with ITAM, initiating downstream signaling. CD3E-CD3G Heterodimer Protein, Cynomolgus (Biotinylated, HEK293, Fc) is a recombinant protein dimer complex containing cynomolgus-derived CD3E-CD3G Heterodimer protein, expressed by HEK293 , with C-hFc labeled tag. CD3E-CD3G Heterodimer Protein, Cynomolgus (Biotinylated, HEK293, Fc), has molecular weight of 44-46 kDa.

HY-P704960

	CD3D-CD3E Heterodimer Protein, Mouse (HEK293, Fc, His, Flag) CD3; CD3e; CD3E; CD3d; T3D; CD3D; CD3E&CD3D; CD3 delta&CD3 epsilon	Mouse	HEK293

HY-P77609

	CD3E-CD3G Heterodimer Protein, Human (HEK293, His) CD3; CD3G; CD3g; T3G; CD3e; CD3E; CD3 epsilon&CD3 gamma; CD3E&CD3G	Human	HEK293
	CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3E-CD3G Heterodimer Protein, Human (HEK293, His) is a recombinant protein dimer complex containing human-derived CD3E-CD3G Heterodimer protein, expressed by HEK293 , with C-His labeled tag. CD3E-CD3G Heterodimer Protein, Human (HEK293, His), has molecular weight of 25-40 kDa.

HY-P77612

	CD3D-CD3E Heterodimer Protein, Human (Biotinylated, HEK293, Fc-Avi) CD3; CD3e; CD3E; CD3d; T3D; CD3D; CD3E&CD3D; CD3 delta&CD3 epsilon	Human	HEK293
	CD3D protein is a component of the TCR-CD3 complex on T lymphocytes and plays a key role in adaptive immunity. It transmits signals through the CD3D, CD3E, CD3G, and CD3Z chains upon TCR engagement. CD3D-CD3E Heterodimer Protein, Human (Biotinylated, HEK293, Fc-Avi) is a recombinant protein dimer complex containing human-derived CD3D-CD3E Heterodimer protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag. CD3D-CD3E Heterodimer Protein, Human (Biotinylated, HEK293, Fc-Avi), has molecular weight of 48-60 kDa.

HY-P77613

	CD3E-CD3G Heterodimer Protein, Human (Biotinylated, HEK293, Fc-Avi) CD3; CD3G; CD3g; T3G; CD3e; CD3E; CD3 epsilon&CD3 gamma; CD3E&CD3G	Human	HEK293
	CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3E-CD3G Heterodimer Protein, Human (Biotinylated, HEK293, Fc-Avi) is a recombinant protein dimer complex containing human-derived CD3E-CD3G Heterodimer protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag. CD3E-CD3G Heterodimer Protein, Human (Biotinylated, HEK293, Fc-Avi), has molecular weight of 48-55 kDa.

HY-P705111

	CD3D-CD3E Heterodimer Protein, Mouse (Biotinylated, HEK293, His-Avi) CD3; CD3e; CD3E; CD3d; T3D; CD3D; CD3E&CD3D; CD3 delta&CD3 epsilon	Mouse	HEK293

HY-P705116

	CD3E-CD3G Heterodimer Protein, Human (Biotinylated, HEK293, His-Avi) CD3; CD3G; CD3g; T3G; CD3e; CD3E; CD3 epsilon&CD3 gamma; CD3E&CD3G	Human	HEK293

HY-P77605

	CD3E-CD3G Heterodimer Protein, Cynomolgus (HEK293, Fc) CD3; CD3G; CD3g; T3G; CD3e; CD3E; CD3 epsilon&CD3 gamma; CD3E&CD3G	Cynomolgus	HEK293
	The CD3E/CD3 epsilon 1-27 peptide is critical in the TCR-CD3 complex, transmitting signals during T cell activation. When APC activates the TCR, CD3E undergoes LCK/FYN-mediated phosphorylation together with ITAM, initiating downstream signaling. CD3E-CD3G Heterodimer Protein, Cynomolgus (HEK293, Fc) is a recombinant protein dimer complex containing cynomolgus-derived CD3E-CD3G Heterodimer protein, expressed by HEK293 , with C-hFc labeled tag. CD3E-CD3G Heterodimer Protein, Cynomolgus (HEK293, Fc), has molecular weight of 36.9 kDa(CD3E) & 36.5 kDa(CD3G), respectively.

HY-P77611

	CD3E-CD3G Heterodimer Protein, Human (HEK293, Fc) CD3; CD3G; CD3g; T3G; CD3e; CD3E; CD3 epsilon&CD3 gamma; CD3E&CD3G	Human	HEK293
	CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3E-CD3G Heterodimer Protein, Human (HEK293, Fc) is a recombinant protein dimer complex containing human-derived CD3E-CD3G Heterodimer protein, expressed by HEK293 , with C-hFc labeled tag. CD3E-CD3G Heterodimer Protein, Human (HEK293, Fc), has molecular weight of 40-60 kDa.

HY-P72726

	CD3D-CD3E Heterodimer Protein, Human (HEK293, His) CD3E & CD3D; CD3 delta & CD3 epsilon; CD3 delta/epsilon	Human	HEK293
	CD3D protein is a component of the TCR-CD3 complex on T lymphocytes and plays a key role in adaptive immunity. It transmits signals through the CD3D, CD3E, CD3G, and CD3Z chains upon TCR engagement. CD3D-CD3E Heterodimer Protein, Human (HEK293, His) is a recombinant protein dimer complex containing human-derived CD3D-CD3E Heterodimer protein, expressed by HEK293 , with C-6*His labeled tag. CD3D-CD3E Heterodimer Protein, Human (HEK293, His), has molecular weight of 16-30 kDa.

HY-P704464

	CD3D-CD3E Heterodimer Protein, Canine (HEK293, His) CD3E & CD3D; CD3 delta & CD3 epsilon; CD3 delta /epsilon	Canine	HEK293

HY-P76237

	CD3E-CD3G Heterodimer Protein, Rhesus Macaque (HEK293, Fc) CD3E & CD3G; CD3 epsilon & CD3 gamma; CD3 epsilon/gamma	Rhesus Macaque	HEK293
	CD3E protein has predicted functions such as SH3 domain binding and protein heterodimerization, and plays a crucial role in nervous system development and cell adhesion. It is involved in T cell activation, cytokine production and signal transduction. CD3E-CD3G Heterodimer Protein, Rhesus Macaque (HEK293, Fc) is a recombinant protein dimer complex containing Rhesus Macaque-derived CD3E-CD3G Heterodimer protein, expressed by HEK293 , with C-hFc labeled tag. CD3E-CD3G Heterodimer Protein, Rhesus Macaque (HEK293, Fc), has molecular weight of ~83 (40 + 43) KDa.

HY-P76802

	CD3D-CD3E Heterodimer Protein, Rhesus Macaque (HEK293, hFc) CD3E & CD3D; CD3 delta & CD3 epsilon; CD3 delta/epsilon	Rhesus Macaque	HEK293
	The CD3D protein is an important component of the TCR-CD3 complex on T lymphocytes and is critical for adaptive immune responses. After APC activates TCR, CD3D, together with CD3E, CD3G and CD3Z, transmits signals through ITAM and activates downstream pathways. CD3D-CD3E Heterodimer Protein, Rhesus Macaque (HEK293, hFc) is a recombinant protein dimer complex containing Rhesus Macaque-derived CD3D-CD3E Heterodimer protein, expressed by HEK293 , with N-hFc.

HY-P704463

	*HRP-Labeled CD3D-CD3E Heterodimer Protein, Human (HEK293, His)* CD3E & CD3D; CD3 delta & CD3 epsilon; CD3 delta /epsilon	Human	HEK293

HY-P70434

	CD3D-CD3E Heterodimer Protein, Human (HEK293, Fc-Flag&Fc-His) CD3E & CD3D; CD3 delta & CD3 epsilon; CD3 delta /epsilon	Human	HEK293
	CD3D protein is a component of the TCR-CD3 complex on T lymphocytes and plays a key role in adaptive immunity. It transmits signals through the CD3D, CD3E, CD3G, and CD3Z chains upon TCR engagement. CD3D-CD3E Heterodimer Protein, Human (HEK293, Fc-Flag&Fc-His) is a recombinant protein dimer complex containing human-derived CD3D-CD3E Heterodimer protein, expressed by HEK293 , with C-hFc, C-Flag, C-6*His labeled tag. CD3D-CD3E Heterodimer Protein, Human (HEK293, Fc-Flag&Fc-His), has molecular weight of 40-52 kDa.

HY-P72727

	CD3D-CD3E Heterodimer Protein, Cynomolgus (HEK293, Fc-Flag&Fc-His) CD3E & CD3D; CD3 delta & CD3 epsilon; CD3 delta/epsilon	Cynomolgus	HEK293
	CD3 δ protein is a component of the TCR-CD3 complex on T lymphocytes and plays a crucial role in adaptive immunity. Activated by APC, TCR signals through the CD3 chain, including CD3D, CD3E, CD3G, and CD3Z. CD3D-CD3E Heterodimer Protein, Cynomolgus (HEK293, Fc-Flag&Fc-His) is a recombinant protein dimer complex containing cynomolgus-derived CD3D-CD3E Heterodimer protein, expressed by HEK293 , with C-hFc, C-Flag, C-6*His labeled tag. CD3D-CD3E Heterodimer Protein, Cynomolgus (HEK293, Fc-Flag&Fc-His), has molecular weight of 40-60 kDa.

HY-P704321

	CD3D-CD3E Heterodimer Protein, Human (HEK293, Llama Fc&Llama Fc) CD3E & CD3D; CD3 delta & CD3 epsilon; CD3 delta /epsilon	Human	HEK293

HY-P704322

	CD3D-CD3E Heterodimer Protein, Cynomolgus (HEK293, Llama Fc&Llama Fc) CD3E & CD3D; CD3 delta & CD3 epsilon; CD3 delta /epsilon	Cynomolgus	HEK293

HY-P704991

	CD3D-CD3E Heterodimer Protein, Cynomolgus (Biotinylated, HEK293, His-Avi) CD3 delta & CD3 epsilon; CD3E & CD3D	Cynomolgus	HEK293

HY-P704216

	CD3E-CD3G Heterodimer Protein, Mouse (HEK293, His, Flag) CD3 epsilon & CD3 gamma; LCD3E & CD3G	Mouse	HEK293

HY-P70091

	CD3 delta Protein, Cynomolgus (HEK293, Fc) rCynT-cell surface glycoprotein CD3 delta chain/CD3d, Fc ; T-cell surface glycoprotein CD3 delta chain; T-cell receptor T3 delta chain; CD3d; CD3D	Cynomolgus	HEK293
	CD3 δ protein is a component of the TCR-CD3 complex on T lymphocytes and plays a crucial role in adaptive immunity. Activated by APC, TCR signals through the CD3 chain, including CD3D, CD3E, CD3G, and CD3Z. CD3 delta Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived CD3 delta protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P704996

	CD3D-CD3E Heterodimer Protein, Human (Biotinylated, HEK293, hFc, His, Avi, Flag) CD3 delta & CD3 epsilon; CD3E & CD3D	Human	HEK293

HY-P76220

	CD3 zeta/CD247 Protein, Human (His) T-cell surface glycoprotein CD3 zeta chain; CD247; CD3Z; T3Z; TCRZ	Human	E. coli
	CD3 zeta/CD247 is a component of the TCR-CD3 complex and can transmit APC-induced TCR signals to initiate immune responses. CD3D, CD3E, CD3G, and CD3Z contain ITAMs that are phosphorylated by LCK and FYN upon TCR engagement, providing docking sites for ZAP70. CD3 zeta/CD247 Protein, Human (His) is the recombinant human-derived CD3 zeta/CD247 protein, expressed by E. coli , with N-His labeled tag.

HY-P72728

	CD3 delta Protein, Cynomolgus (HEK293, His) T-cell surface glycoprotein CD3 delta chain; T-cell receptor T3 delta chain; CD3d; CD3D	Cynomolgus	HEK293
	CD3 δ protein is a component of the TCR-CD3 complex on T lymphocytes and plays a crucial role in adaptive immunity. Activated by APC, TCR signals through the CD3 chain, including CD3D, CD3E, CD3G, and CD3Z. CD3 delta Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived CD3 delta protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P72899

	CD3E-CD3G Heterodimer Protein, Human (HEK293, Fc-Flag & mFc) T-cell surface glycoprotein CD3 epsilon chain; CD3E; T3E; CD3 epsilon	Human	HEK293
	CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3E-CD3G Heterodimer Protein, Human (HEK293, Fc-Flag & mFc) is a recombinant protein dimer complex containing human-derived CD3E-CD3G Heterodimer protein, expressed by HEK293 , with C-hFc, C-Flag, C-mFc labeled tag. CD3E-CD3G Heterodimer Protein, Human (HEK293, Fc-Flag & mFc), has molecular weight of 42-47 kDa.

HY-P71845

	CD3 gamma Protein, Cynomolgus (P.pastoris, His) CD3GT-cell surface glycoprotein CD3 gamma chain; T-cell receptor T3 gamma chain; CD antigen CD3g	Cynomolgus	P. pastoris
	CD3γ protein on lymphocytes is a component of the TCR-CD3 complex and is critical for adaptive immune responses. When the TCR is activated, CD3D, CD3E, CD3G, and CD3Z transmit TCR-mediated signals and activate downstream pathways. CD3 gamma Protein, Cynomolgus (P.pastoris, His) is the recombinant cynomolgus-derived CD3 gamma protein, expressed by P. pastoris , with N-His labeled tag.

HY-P705463

	CD3 delta Protein, Cynomolgus (HEK293, Fc-His) T-cell surface glycoprotein CD3 delta chain; T-cell receptor T3 delta chain; CD3d; CD3D	Cynomolgus	HEK293

HY-P70506

	CD3 epsilon Protein, Human (HEK293, His) T-Cell Surface Glycoprotein CD3 Epsilon Chain; T-Cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Human	HEK293
	CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3 epsilon Protein, Human (HEK293, His) is the recombinant human-derived CD3 epsilon protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P76788

	CD3 epsilon Protein, Rat (HEK293, Fc) T-Cell Surface Glycoprotein CD3 Epsilon Chain; T-Cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Rat	HEK293
	CD3 epsilon Protein, a vital component of the TCR-CD3 complex on T-lymphocytes, is pivotal for adaptive immune responses. CD3E is crucial for proper T-cell development and contributes to TCR-CD3 complex internalization and down-regulation. CD3 epsilon Protein, Rat (HEK293, Fc) is the recombinant rat-derived CD3 epsilon protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P77320

	CD3 epsilon Protein, Canine (HEK293, Fc) T-Cell Surface Glycoprotein CD3 Epsilon Chain; T-Cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Canine	HEK293
	The CD3 ε protein on lymphocytes is a component of the TCR-CD3 complex and is critical for adaptive immune responses. When APC is activated, TCR signals transmitted by CD3D, CD3E, CD3G, and CD3Z initiate pathways through ITAM. CD3 epsilon Protein, Canine (HEK293, Fc) is the recombinant canine-derived CD3 epsilon protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P704465

	CD3 epsilon Protein, Canine (HEK293, His) T-Cell Surface Glycoprotein CD3 Epsilon Chain; T-Cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Canine	HEK293
	The CD3 ε protein on lymphocytes is a component of the TCR-CD3 complex and is critical for adaptive immune responses. When APC is activated, TCR signals transmitted by CD3D, CD3E, CD3G, and CD3Z initiate pathways through ITAM. CD3 epsilon Protein, Canine (HEK293, His) is the recombinant canine-derived CD3 epsilon protein, expressed by HEK293, with C-His labeled tag.

HY-P76791

	CD3 epsilon Protein, Rhesus Macaque (HEK293, His) T-Cell Surface Glycoprotein CD3 Epsilon Chain; T-Cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Rhesus Macaque	HEK293
	CD3 epsilon Protein, a vital component of the TCR-CD3 complex on T-lymphocytes, is pivotal for adaptive immune responses. CD3E is crucial for proper T-cell development and contributes to TCR-CD3 complex internalization and down-regulation. CD3 epsilon Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived CD3 epsilon protein, expressed by HEK293 , with C-His labeled tag.

HY-P76789

	CD3 epsilon Protein, Rhesus Macaque (HEK293, Fc) T-Cell Surface Glycoprotein CD3 Epsilon Chain; T-Cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Rhesus Macaque	HEK293
	CD3 epsilon Protein, a vital component of the TCR-CD3 complex on T-lymphocytes, is pivotal for adaptive immune responses. CD3E is crucial for proper T-cell development and contributes to TCR-CD3 complex internalization and down-regulation. CD3 epsilon Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived CD3 epsilon protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P704462

	*HRP-Labeled CD3* epsilon Protein, Human (HEK293, His)** T-Cell Surface Glycoprotein CD3 Epsilon Chain; T-Cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Human	HEK293
	CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. HRP-Labeled CD3 epsilon Protein, Human (HEK293, His) is the recombinant human-derived HRP-Labeled CD3 epsilon protein, expressed by HEK293, with C-His labeled tag.

HY-P70682

	CD3 epsilon Protein, Human (104a.a, HEK293, Fc) T-Cell Surface Glycoprotein CD3 Epsilon Chain; T-Cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Human	HEK293
	CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3 epsilon Protein, Human (104a.a, HEK293, Fc) is the recombinant human-derived CD3 epsilon protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P70824

	CD3 epsilon 1-27 peptide Protein, Human (HEK293, mFc) T-Cell Surface Glycoprotein CD3 Epsilon Chain; T-Cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Human	HEK293
	CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3 epsilon 1-27 peptide Protein, Human (HEK293, mFc) is the recombinant human-derived CD3 epsilon protein, expressed by HEK293 , with C-mFc labeled tag.

HY-P705464

	CD3 epsilon Protein, Human (104a.a, HEK293, Fc-His) T-Cell Surface Glycoprotein CD3 Epsilon Chain; T-Cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E	Human	HEK293

HY-P7879

	CD3D Protein, Human (HEK293, His) rHuT-cell surface glycoprotein CD3 delta chain/CD3D, His; T-Cell Surface Glycoprotein CD3 Delta Chain; T-Cell Receptor T3 Delta Chain; CD3d; CD3D; T3D	Human	HEK293
	CD3D protein is a component of the TCR-CD3 complex on T lymphocytes and plays a key role in adaptive immunity. It transmits signals through the CD3D, CD3E, CD3G, and CD3Z chains upon TCR engagement. CD3D Protein, Human (HEK293, His) is the recombinant human-derived CD3D protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P78753

	CD3 gamma Protein, Human (HEK293, Fc) CD3G; CD3-GAMMA; IMD17; T3G; TCR gamma	Human	HEK293
	CD3 gamma is part of the TCR-CD3 complex on T lymphocytes, promoting TCR-mediated signaling and regulating surface expression. APC-induced TCR activation promotes CD3 gamma as well as CD3D, CD3E, and CD3Z signaling through ITAMs. CD3 gamma Protein, Human (HEK293, Fc) is the recombinant human-derived CD3 gamma protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P78874

	CD3 epsilon Protein, Human (Biotinylated, HEK293, His) FLJ18683; T3E; TCRE; CD3E; CD3-epsilon	Human	HEK293
	CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3 epsilon Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived CD3 epsilon protein, expressed by HEK293 , with C-His labeled tag.

HY-P70090

	CD3 epsilon Protein, Cynomolgus (HEK293, Fc) rCynT-cell surface glycoprotein CD3 epsilon chain/CD3E, Fc ; CD3 epsilon; CD3e antigen; CD3e antigen, epsilon polypeptide (TiT3 complex); CD3e molecule, epsilon (CD3-TCR complex); CD3e; CD3-epsilon; FLJ18683; T3E; T-cell antigen receptor complex, epsilon subunit of T3; T-cell surface antigen T3/Leu-4 epsilon chain;	Cynomolgus	HEK293
	The CD3E/CD3 epsilon 1-27 peptide is critical in the TCR-CD3 complex, transmitting signals during T cell activation. When APC activates the TCR, CD3E undergoes LCK/FYN-mediated phosphorylation together with ITAM, initiating downstream signaling. CD3 epsilon Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived CD3 epsilon protein, expressed by HEK293 , with C-Fc, C-hFc labeled tag.

HY-P78269

	CD3 epsilon Protein, Cynomolgus (HEK293, His) CD3e; CD3E; T3E; FLJ18683; TCRE; CD3-epsilon; IMD18	Cynomolgus	HEK293
	The CD3E/CD3 epsilon 1-27 peptide is critical in the TCR-CD3 complex, transmitting signals during T cell activation. When APC activates the TCR, CD3E undergoes LCK/FYN-mediated phosphorylation together with ITAM, initiating downstream signaling. CD3 epsilon Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived CD3 epsilon protein, expressed by HEK293 , with C-His labeled tag.

HY-P75414

	CD3E-CD3G Heterodimer Protein, Mouse (HEK293, Fc) AI504783 Protein; CD3 Protein; CD3epsilon Protein; T3e Protein	Mouse	HEK293
	CD3E protein has predicted functions such as SH3 domain binding and protein heterodimerization, and plays a crucial role in nervous system development and cell adhesion. It is involved in T cell activation, cytokine production and signal transduction. CD3E-CD3G Heterodimer Protein, Mouse (HEK293, Fc) is a recombinant protein dimer complex containing mouse-derived CD3E-CD3G Heterodimer protein, expressed by HEK293 , with C-hFc labeled tag. CD3E-CD3G Heterodimer Protein, Mouse (HEK293, Fc), has molecular weight of ~38-40 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (10) Rabbit (10)
Reactivity:	Human (20) Rat (1) Mouse (1)
Application:	IHC-P (11) ICC/IF (7) mIHC (1) IF-Tissue (1) IP (10) IHC-F (2) WB (17) FC (10) ELISA (10)
Isotype:	IgG (10) IgG1 (6) IgG2b (2)
Conjugation:	PE (1) Non-conjugated (19) Biotin (14) AF 488 (1)
Clonality:	Monoclonal (11) Monoclonal Antibody (1) Recombinant (5)
Modification:	Phosphorylated (1) Unmodified (11)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P810532-PE

	CD3 Antibody (PE) (YA9802） CD3	FC	Human

HY-P80601

	CD3G Antibody (YA538) CD3 gamma; CD3g; T3G	WB, IHC-P, IP	Human
	CD3G Antibody (YA538) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD3G.

HY-P86568

	CD3 epsilon Antibody (YA6260) T-cell surface glycoprotein CD3 epsilon chain; T-cell surface antigen T3/Leu-4 epsilon chain; CD antigen CD3e;	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	CD3 epsilon Antibody (YA6260) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD3 epsilon.

HY-P80598

	CD3 epsilon Antibody (YA542) 1 Publications Verification CD3E; T3E; T-cell surface glycoprotein CD3 epsilon chain; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e	WB, IHC-P, IP	Human
	CD3 epsilon Antibody (YA542) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD3 epsilon.

HY-P80601A

	CD3G Antibody (YA538)(PBS only) CD3 gamma; CD3g; T3G	WB, IHC-P, IP	Human
	CD3G Antibody (YA538) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD3G.

HY-P83994

	CD3 epsilon Antibody (YA3691) T3E; TCRE; FLJ18683; CD3E	WB, FC, ELISA	Human
	CD3 epsilon Antibody (YA3691) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD3 epsilon.

HY-P80598A

	CD3 epsilon Antibody (YA542)(PBS only) CD3E; T3E; T-cell surface glycoprotein CD3 epsilon chain; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e	WB, IHC-P, IP	Human
	CD3 epsilon Antibody (YA542) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD3 epsilon.

HY-P86804

	CD3 epsilon Antibody (YA6497) 1 Publications Verification 4930549J05Rik antibody; A430104F18Rik antibody; AW552088 antibody; CD247 antibody; CD3 antibody; CD3 delta antibody; CD3 epsilon antibody; CD3 eta antibody; CD3 gamma antibody; CD3 zeta antibody; CD3H antibody; CD3Q antibody; CD3Z antibody; CD3zeta antibody; Ctg3 antibody; FLJ17620 antibody; FLJ17664 antibody; FLJ18683 antibody; FLJ79544 antibody FLJ94613 antibody; IMD19 antibody; Leu-4 antibody; MGC138597 antibody; OKT3, delta chain antibody; OTTHUMP00000032544 antibody; T cell receptor antibody; T3 antibody; T3d antibody; T3e antibody; T3g antibody; T3z antibody; TCRE antibody; TCRk antibody; Tcrz antibody; TCRzeta antibody	WB, IHC-P, ICC/IF, IP, IF-Tissue, mIHC	Human
	CD3 epsilon Antibody (YA6497) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD3 epsilon.

HY-P85086

	CD3 zeta Antibody (YA4778) CD247; CD3Z; T3Z; TCRZ; T-cell surface glycoprotein CD3 zeta chain; T-cell receptor T3 zeta chain; CD antigen CD247	WB, IHC-P, ICC/IF, FC, ELISA	Human
	CD3 zeta Antibody (YA4778) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CD3 zeta.

HY-P83994A

	CD3 epsilon Antibody (YA3691)(PBS only) T3E; TCRE; FLJ18683; CD3E	WB, FC, ELISA	Human
	CD3 epsilon Antibody (YA3691) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD3 epsilon.

HY-P84176

	CD3 zeta Antibody (YA3873) T3Z; CD3H; CD3Q; CD3Z; TCRZ; CD3-ZETA; CD247	IHC-P, ICC/IF, FC, ELISA	Human
	CD3 zeta Antibody (YA3873) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD3 zeta.

HY-P84176A

	CD3 zeta Antibody (YA3873)(PBS only) T3Z; CD3H; CD3Q; CD3Z; TCRZ; CD3-ZETA; CD247	IHC-P, ICC/IF, FC, ELISA	Human
	CD3 zeta Antibody (YA3873) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD3 zeta.

HY-P80600

	CD3D Antibody (YA539) CD3D; T3D; T-cell surface glycoprotein CD3 delta chain; T-cell receptor T3 delta chain; CD antigen CD3d	WB, IHC-F, IHC-P, ICC/IF, IP	Human
	CD3D Antibody (YA539) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD3D.

HY-P80600A

	CD3D Antibody (YA539)(PBS only) CD3D; T3D; T-cell surface glycoprotein CD3 delta chain; T-cell receptor T3 delta chain; CD antigen CD3d	WB, IHC-F, IHC-P, ICC/IF, IP	Human
	CD3D Antibody (YA539) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD3D.

HY-P82680

	*Phospho-CD3* zeta (Tyr142) Antibody (YA2425)** CD247; CD3Z; T3Z; TCRZ; T-cell surface glycoprotein CD3 zeta chain; T-cell receptor T3 zeta chain; CD antigen CD247	WB, IP	Human
	Phospho-CD3 zeta (Tyr142) Antibody (YA2425) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-CD3 zeta (Tyr142).

HY-P82680A

	*Phospho-CD3* zeta (Tyr142) Antibody (YA2425)(PBS only)** CD247; CD3Z; T3Z; TCRZ; T-cell surface glycoprotein CD3 zeta chain; T-cell receptor T3 zeta chain; CD antigen CD247	WB, IP	Human
	Phospho-CD3 zeta (Tyr142) Antibody (YA2425) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-CD3 zeta (Tyr142).

HY-P83942

	CD3D Antibody (YA3639) T3D; IMD19; CD3-DELTA	WB, FC, ELISA	Human
	CD3D Antibody (YA3639) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to CD3D.

HY-P84033

	CD3G Antibody (YA3730) T3G; IMD17; CD3-GAMMA	WB, FC, ELISA	Human
	CD3G Antibody (YA3730) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD3G.

HY-P83942A

	CD3D Antibody (YA3639)(PBS only) T3D; IMD19; CD3-DELTA	WB, FC, ELISA	Human
	CD3D Antibody (YA3639) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to CD3D.

HY-P84033A

	CD3G Antibody (YA3730)(PBS only) T3G; IMD17; CD3-GAMMA	WB, FC, ELISA	Human
	CD3G Antibody (YA3730) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD3G.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-17413S1

Zidovudine-13C,d3 Azidothymidine-¹³C,d₃; AZT-¹³C,d₃; ZDV-¹³C,d₃		Azide
Zidovudine- ¹³C,d₃ is the ¹³C- and deuterium labeled Zidovudine. Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI), widely used to treat HIV infection.

Cat. No.	Product Name		Classification

HY-169480

Lipid C2		Cationic Lipids
Lipid C2 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNP) for mRNA delivery in vivo. LNPs containing Lipid C2 and encapsulating an mRNA reporter selectively accumulate in the liver and spleen but not the heart, lungs, or kidneys in mice. LNP containing Lipid C2 and encapsulating mRNA encoding the Epstein-Barr virus (EBV) protein latent membrane protein 2 (LMP-2), in combination with an anti-programmed cell death protein 1 (PD-1) antibody, decrease tumor volume and reverse T cell exhaustion, as well as increase the percentage of CD3 ⁺CD8 ⁺ central and CD3 ⁺CD8 ⁺ effector memory T cells and decrease the percentage of CD3 ⁺ T cells expressing Pd-1, in the spleen in a CT26 murine EBV-infected colon cancer model .

HY-RS02243

CD3E Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
CD3E Human Pre-designed siRNA Set A contains three designed siRNAs for CD3E gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS02242

CD3D Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
CD3D Human Pre-designed siRNA Set A contains three designed siRNAs for CD3D gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS23464

Cd3e Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Cd3e Rat Pre-designed siRNA Set A contains three designed siRNAs for Cd3e gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS24205

Cd3d Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Cd3d Rat Pre-designed siRNA Set A contains three designed siRNAs for Cd3d gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS02244

CD3G Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
CD3G Human Pre-designed siRNA Set A contains three designed siRNAs for CD3G gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS17740

Cd3d Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Cd3d Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cd3d gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS17366

Cd3g Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Cd3g Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cd3g gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS01740

C2CD3 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
C2CD3 Human Pre-designed siRNA Set A contains three designed siRNAs for C2CD3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS21508

Cd247 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Cd247 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cd247 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS17021

Cd3e Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Cd3e Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cd3e gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS23820

Cd3g Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Cd3g Rat Pre-designed siRNA Set A contains three designed siRNAs for Cd3g gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CD3

Inhibitors & Agonists

Peptides

MCE Kits

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Natural
Products